Chung-Han Lee

Nov 7, 2024 | mdpi.com | Ming-Hsu Tsai |Chung-Han Lee |Aaron Wu |Yao-Ning Lei

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

May 21, 2024 | europeanurology.com | Matthew Taylor |James J. Hsieh |Regina Gironés Sarrió |Christopher Di Simone |Chung-Han Lee |Amishi Yogesh Shah | +10 more

1 Taylor M.H. Lee C.H. Makker V. et al. Phase Ib/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 38: 1154-1163 ]. In the RCC cohort, LEN + PEM exhibited antitumor activity irrespective of prior treatment, and notably among patients who had received prior immune checkpoint inhibitors (ICIs) [ 2 Lee C.H. Shah A.Y. Rasco D. et al.

Sep 24, 2023 | targetedonc.com | Chung-Han Lee

Chung-Han Lee, MD, PhD, vice president of early clinical development at Exelixis, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma (RCC). According to Lee, the space is in need of better predictive markers on whether or not patients have reccurrent disease, improved methods of determining which patients will respond to treatment, and the ability to predict who may develop toxicities.

Jul 14, 2023 | onclive.com | Chung-Han Lee

Dr Choueiri on Trials in Progress in Advanced Renal Cell CarcinomaDr McDermott on the Ongoing LITESPARK-024 Trial in Pretreated Advanced RCCFrontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCCAdjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages

Jul 10, 2023 | urotoday.com | Chung-Han Lee

Read the Full Video TranscriptPedro Barata: Hi, I'm Pedro Barata. I'm a GU Oncologist at University Hospital, Seidman Cancer Center, Case Western University in Cleveland, Ohio. It's my true pleasure to be joined today by my colleague and friend, Dr. Lee, from Memorial Sloan Kettering in New York. Welcome. Chung-Han Lee: Thank you, Pedro. Glad to be here. Thank you for having me. Pedro Barata: Absolutely.